Pfizer 2005 Annual Report Download - page 73

Download and view the complete annual report

Please find page 73 of the 2005 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

72 2005 Financial Report
Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc and Subsidiary Companies
QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH
2004
Revenues $12,487 $12,274 $12,831 $14,924
Costs and expenses 8,156 8,557 8,690 10,842
Merger-related in-process research and development charges 955 — — 116
Restructuring charges and merger-related costs 247 289 190 467
Income from continuing operations before provision for taxes
on income, and minority interests 3,129 3,428 3,951 3,499
Provision for taxes on income 809 582 650 625
Minority interests 2 2 3 3
Income from continuing operations 2,318 2,844 3,298 2,871
Discontinued operations:
Income/(loss) from discontinued operations—net of tax 13 17 (3) (49)
Gains on sales of discontinued operations—net of tax — 2 46 3
Discontinued operations—net of tax 13 19 43 (46)
Net income $ 2,331 $ 2,863 $ 3,341 $ 2,825
Earnings per common share—basic:
Income from continuing operations $ 0.31 $ 0.38 $ 0.44 $ 0.39
Discontinued operations—net of tax — — 0.01 (0.01)
Net income $ 0.31 $ 0.38 $ 0.45 $ 0.38
Earnings per common share—diluted:
Income from continuing operations $ 0.30 $ 0.38 $ 0.43 $ 0.39
Discontinued operations—net of tax — — 0.01 (0.01)
Net income $ 0.30 $ 0.38 $ 0.44 $ 0.38
Cash dividends paid per common share $ 0.17 $ 0.17 $ 0.17 $ 0.17
Stock prices
High $ 38.89 $ 37.90 $ 34.63 $ 31.50
Low $33.50 $ 33.82 $ 29.60 $ 21.99
All financial information reflects the following as discontinued
operations: our in-vitro allergy and autoimmune diagnostics
testing, surgical ophthalmics, certain European generics, as well as
certain non-core consumer healthcare product lines (primarily
marketed in Europe) and the femhrt, Loestrin and Estrostep
women’s health product lines (see Note 3, Dispositions).
Merger-related in-process research and development charges
primarily includes amounts incurred in connection with our
acquisition of Esperion (see Note 2B, Acquisitions: Other
Acquisitions).
Restructuring charges and merger-related costs include
integration and restructuring costs primarily related to our
acquisition of Pharmacia (see Note 5, Merger-Related Costs).